1

NationalInstituteonDrugAbuse(NIDA)MisuseofPrescriptionDrugsLastUpdatedDecember2018https://www.drugabuse.gov

2

TableofContentsMisuseofPrescriptionDrugs

Overview

Whatisthescopeofprescriptiondrugmisuse?

Isitsafetouseprescriptiondrugsincombinationwithothermedications?

Whatclassesofprescriptiondrugsarecommonlymisused?

Areprescriptiondrugssafetotakewhenpregnant?

Howcanprescriptiondrugmisusebeprevented?

Howcanprescriptiondrugaddictionbetreated?

WherecanIgetfurtherinformationaboutprescriptiondrugmisuse?

References

3

Overview

Misuseofprescriptiondrugsmeanstakingamedicationinamannerordoseotherthanprescribed;takingsomeoneelse’sprescription,evenifforalegitimatemedicalcomplaintsuchaspain;ortakingamedicationtofeeleuphoria(i.e.,togethigh).Thetermnonmedicaluseofprescriptiondrugsalsoreferstothesecategoriesofmisuse.Thethreeclassesofmedicationmostcommonlymisusedare:

opioids—usuallyprescribedtotreatpain

centralnervoussystem[CNS]depressants(thiscategoryincludestranquilizers,sedatives,andhypnotics)—usedtotreatanxietyandsleepdisorders

stimulants—mostoftenprescribedtotreatattention-deficithyperactivitydisorder(ADHD)

Prescriptiondrugmisusecanhaveseriousmedicalconsequences.Increasesinprescriptiondrugmisuse overthelast15yearsarereflectedinincreasedemergencyroomvisits,overdosedeathsassociatedwithprescriptiondrugs ,andtreatmentadmissionsforprescriptiondrugusedisorders,themostsevereformofwhichisanaddiction.Overdosedeathsinvolvingprescriptionopioidswerefivetimeshigherin2016thanin1999.

©iStock.com/ognianm

1

2–5

6

4

Whatisthescopeofprescriptiondrugmisuse?

Misuseofprescriptionopioids,CNSdepressants,andstimulantsisaseriouspublichealthproblemintheUnitedStates.Althoughmostpeopletakeprescriptionmedicationsresponsibly,in2017,anestimated18millionpeople(morethan6percentofthoseaged12andolder)havemisusedsuchmedicationsatleastonceinthepastyear.Accordingtoresultsfromthe2017NationalSurveyonDrugUseandHealth,anestimated2millionAmericansmisusedprescriptionpainrelieversforthefirsttimewithinthepastyear,whichaveragestoapproximately5,480initiatesperday.Additionally,morethanonemillionmisusedprescriptionstimulants,1.5millionmisusedtranquilizers,and271,000misusedsedativesforthefirsttime.

Thereasonsforthehighprevalenceofprescriptiondrugmisusevarybyage,gender,andotherfactors,butlikelyincludeeaseofaccess.Thenumberofprescriptionsforsomeofthesemedicationshasincreaseddramaticallysincetheearly1990s. Moreover,misinformationabouttheaddictivepropertiesofprescriptionopioidsandtheperceptionthatprescriptiondrugsarelessharmfulthanillicitdrugsareotherpossiblecontributorstotheproblem. AlthoughmisuseofprescriptiondrugsaffectsmanyAmericans,certainpopulationssuchasyouthandolderadultsmaybeatparticularrisk.

AdolescentsandYoungAdults

Misuseofprescriptiondrugsishighestamongyoungadultsages18to25,with14.4percentreportingnonmedicaluseinthepastyear.Amongyouthages12to17,4.9percentreportedpast-yearnonmedicaluseofprescriptionmedications.

Afteralcohol,marijuana,andtobacco,prescriptiondrugs(taken

7

9

10

11,12

13,14

16

th

5

nonmedically)areamongthemostcommonlyuseddrugsby12graders.NIDA’sMonitoringtheFuturesurveyofsubstanceuseandattitudesinteensfoundthatabout6percentofhighschoolseniorsreportedpast-yearnonmedicaluseoftheprescriptionstimulantAdderall in2017,and2percentreportedmisusingtheopioidpainrelieverVicodin .

Althoughpast-yearnonmedicaluseofCNSdepressantshasremainedfairlystableamong12 graderssince2012,useofprescriptionopioidshasdeclinedsharply.Forexample,past-yearnonmedicaluseofVicodinamong12 graderswasreportedby9.6percentin2002anddeclinedto2.0percentin2017.NonmedicaluseofAdderall increasedbetween2009and2013,buthasbeendecreasingthrough2017.Whenaskedhowtheyobtainedprescriptionstimulantsfornonmedicaluse,around60percentoftheadolescentsandyoungadultssurveyedsaidtheyeitherboughtorreceivedthedrugsfromafriendorrelative.

Youthwhomisuseprescriptionmedicationsarealsomorelikelytoreportuseofotherdrugs.Multiplestudieshaverevealedassociationsbetweenprescriptiondrugmisuseandhigherratesofcigarettesmoking;heavyepisodicdrinking;andmarijuana,cocaine,andotherillicitdruguseamongU.S.adolescents,youngadults,andcollegestudents. Inthecaseofprescriptionopioids,receivingalegitimateprescriptionforthesedrugsduringadolescenceisalsoassociatedwithagreaterriskoffutureopioidmisuse,particularlyinyoungadultswhohavelittletonohistoryofdruguse.

OlderAdults

th

®

® 17

th

th

®

17

18–21

14

6

Morethan80percentofolderpatients(ages57to85years)useatleastoneprescriptionmedicationonadailybasis,withmorethan50percenttakingmorethanfivemedicationsorsupplementsdaily. Thiscanpotentiallyleadtohealthissuesresultingfromunintentionallyusingaprescriptionmedicationinamannerotherthanhowitwasprescribed,orfromintentionalnonmedicaluse.Thehighratesofmultiple(comorbid)chronicillnessesinolderpopulations,age-relatedchangesindrugmetabolism,andthepotentialfordruginteractionsmakemedication(andothersubstance)misusemoredangerousinolderpeoplethaninyoungerpopulations. Further,alargepercentageofolderadultsalsouseover-the-countermedicinesanddietaryandherbalsupplements,whichcouldcompoundanyadversehealthconsequencesresultingfromnonmedicaluseofprescriptiondrugs.

©Shutterstock/DavidSmart

13

22

13

7

Isitsafetouseprescriptiondrugsincombinationwithothermedications?

Thesafetyofusingprescriptiondrugsincombinationwithothersubstancesdependsonanumberoffactorsincludingthetypesofmedications,dosages,othersubstanceuse(e.g.,alcohol),andindividualpatienthealthfactors.Patientsshouldtalkwiththeirhealthcareprovideraboutwhethertheycansafelyusetheirprescriptiondrugswithothersubstances,includingprescriptionandover-the-counter(OTC)medications,aswellasalcohol,tobacco,andillicitdrugs.Specifically,drugsthatslowdownbreathingrate,suchasopioids,alcohol,antihistamines,CNSdepressants,orgeneralanesthetics,shouldnotbetakentogetherbecausethesecombinationsincreasetheriskoflife-threateningrespiratorydepression.Stimulantsshouldalsonotbeusedwithothermedicationsunlessrecommendedbyaphysician.PatientsshouldbeawareofthedangersassociatedwithmixingstimulantsandOTCcoldmedicinesthatcontaindecongestants,ascombiningthesesubstancesmaycausebloodpressuretobecomedangerouslyhighorleadtoirregularheartrhythms.

4,26

27

8

Whatclassesofprescriptiondrugsarecommonlymisused?

Opioids

Whatareopioids?

Opioidsaremedicationsthatactonopioidreceptorsinboththespinalcordandbraintoreducetheintensityofpain-signalperception.Theyalsoaffectbrainareasthatcontrolemotion,whichcanfurtherdiminishtheeffectsofpainfulstimuli.Theyhavebeenusedforcenturiestotreatpain,cough,anddiarrhea. Themostcommonmodernuseofopioidsistotreatacutepain.However,sincethe1990s,theyhavebeenincreasinglyusedtotreatchronicpain,despitesparseevidencefortheireffectivenesswhenusedlongterm. Indeed,somepatientsexperienceaworseningoftheirpainorincreasedsensitivitytopainasaresultoftreatmentwithopioids,aphenomenonknownashyperalgesia.

Importantly,inadditiontorelievingpain,opioidsalsoactivaterewardregionsinthebraincausingtheeuphoria—orhigh—thatunderliesthepotentialformisuseandsubstanceusedisorder.Chemically,thesemedicationsareverysimilartoheroin,whichwasoriginallysynthesizedfrommorphineasapharmaceuticalinthelate19thcentury. Thesepropertiesconferanincreasedriskofsubstanceusedisordereveninpatientswhotaketheirmedicationasprescribed.

Overdoseisanothersignificantdangerwithopioids,becausethesecompoundsalsointeractwithpartsofthebrainstemthatcontrolbreathing.Takingtoomuchofanopioidcansuppressbreathingenoughthattheusersuffocates.Anoverdosecanbereversed(andfatalityprevented)ifthecompoundnaloxoneisadministeredquickly(see"ReversinganOpioidOverdosewithNaloxone").

28

29

30

31

29

9

Prescriptionopioidmedicationsincludehydrocodone(e.g.,Vicodin ),oxycodone(e.g.,OxyContin ,Percocet ),oxymorphone(e.g.,Opana ),morphine(e.g.,Kadian ,Avinza ),codeine,fentanyl,andothers.HydrocodoneproductsarethemostcommonlyprescribedintheUnitedStatesforavarietyofindications,includingdental-andinjury-relatedpain. Oxycodoneandoxymorphonearealsoprescribedformoderatetoseverepainrelief. Morphineisoftenusedbeforeandaftersurgicalprocedurestoalleviateseverepain,andcodeineistypicallyprescribedformilderpain. Inadditiontotheirpain-relievingproperties,someofthesedrugs—codeineanddiphenoxylate(Lomotil ),forexample—areusedtorelievecoughsandseverediarrhea.

Howdoopioidsaffectthebrainandbody?

Opioidsactbyattachingtoandactivatingopioidreceptorproteins,whicharefoundonnervecellsinthebrain,spinalcord,gastrointestinaltract,andotherorgansinthebody. Whenthesedrugsattachtotheirreceptors,theyinhibitthetransmissionofpainsignals.Opioidscanalsoproducedrowsiness,mentalconfusion,nausea,constipation,andrespiratorydepression,andsincethesedrugsalsoactonbrainregionsinvolvedinreward,theycaninduceeuphoria,particularlywhentheyaretakenatahigher-than-prescribeddoseoradministeredinotherwaysthanintended. Forexample,OxyContin isanoralmedicationusedtotreatmoderatetoseverepainthroughaslow,steadyreleaseoftheopioid.SomepeoplewhomisuseOxyContin intensifytheirexperiencebysnortingorinjectingit. Thisisaverydangerouspractice,greatlyincreasingtheperson’sriskforseriousmedicalcomplications,includingoverdose

® ® ®

® ® ®

32

33,34

28

®

28

28

28 ®

®

35

10

UnderstandingDependence,Addiction,andTolerance

Dependenceoccursasaresultofphysiologicaladaptationstochronicexposuretoadrug.Itisoftenapartofaddiction,buttheyarenotequivalent.Addictioninvolvesotherchangestobraincircuitryandisdistinguishedbycompulsivedrugseekingandusedespitenegativeconsequences.

Thosewhoaredependentonamedicationwillexperienceunpleasantphysicalwithdrawalsymptomswhentheyabruptlyreduceorstopuseofthedrug.Thesesymptomscanbemildtosevere(dependingonthedrug)andcanusuallybemanagedmedicallyoravoidedbyslowlytaperingdownthedrugdosage.

Tolerance,ortheneedtotakehigherdosesofamedicationtogetthesameeffect,oftenaccompaniesdependence.Whentoleranceoccurs,itcanbedifficultforaphysiciantoevaluatewhetherapatientisdevelopingadrugproblemorhasamedicalneedforhigherdosestocontrolhisorhersymptoms.Forthisreason,physiciansshouldbevigilantandattentivetotheirpatients’symptomsandleveloffunctioningandshouldscreenforsubstancemisusewhentoleranceordependenceispresent.

Whatarethepossibleconsequencesofprescriptionopioidmisuse?

36

37

29

11

Whentakenasprescribed,patientscanoftenuseopioidstomanagepainsafelyandeffectively.However,itispossibletodevelopasubstanceusedisorderwhentakingopioidmedicationsasprescribed.Thisriskandtheriskforoverdoseincreasewhenthesemedicationsaremisused.Evenasinglelargedoseofanopioidcancausesevererespiratorydepression(slowingorstoppingofbreathing),whichcanbefatal;takingopioidswithalcoholorsedativesincreasesthisrisk.

Whenproperlymanaged,short-termmedicaluseofopioidpainrelievers—takenforafewdaysfollowingoralsurgery,forinstance—rarelyleadstoanopioidusedisorderoraddiction.Butregular(e.g.,severaltimesaday,forseveralweeksormore)orlonger-termuseofopioidscanleadtodependence(physicaldiscomfortwhennottakingthedrug),tolerance(diminishedeffectfromtheoriginaldose,leadingtoincreasingtheamounttaken),and,insomecases,addiction(compulsivedrugseekinganduse)(see"UnderstandingDependence,Addiction,andTolerance").Withbothdependenceandaddiction,withdrawalsymptomsmayoccurifdruguseissuddenlyreducedorstopped.Thesesymptomsmayincluderestlessness,muscleandbonepain,insomnia,diarrhea,vomiting,coldflasheswithgoosebumps,andinvoluntarylegmovements.

©iStock.com/Sezeryadigar

4,26

31

12

Misuseofprescriptionopioidsisalsoariskfactorfortransitioningtoheroinuse.ReadmoreabouttherelationshipbetweenprescriptionopioidsandheroininNIDA'sPrescriptionOpioidsandHeroinResearchReport.

Howisprescriptionopioidmisuserelatedtochronicpain?

Healthcareprovidershavelongwrestledwithhowbesttotreatthemorethan100millionAmericanswhosufferfromchronicpain. Opioidshavebeenthemostcommontreatmentforchronicpainsincethelate1990s,butrecentresearchhascastdoubtbothontheirsafetyandtheirefficacyinthetreatmentofchronicpainwhenitisnotrelatedtocancerorpalliativecare. Thepotentialrisksinvolvedwithlong-termopioidtreatment,suchasthedevelopmentofdrugtolerance,hyperalgesia,andaddiction,presentdoctorswithadilemma,asthereislimitedresearchonalternativetreatmentsforchronicpain.Patientsthemselvesmayevenbereluctanttotakeanopioidmedicationprescribedtothemforfearofbecomingaddicted.

Estimatesoftherateofopioidmisuseamongchronicpainpatientsvarywidelyasaresultofdifferencesintreatmentduration,insufficientresearchonlong-termoutcomes,disparatestudypopulations,anddifferentoutcomemeasures(e.g.,dependenceversusOUDoraddiction).OnestudyassessingcurrentcriteriaforOUDinalargenumberofchronicpainpatientsreceivingopioidsfoundthat28.1percenthadmildOUD,9.7percenthadmoderateOUD,and3.5percenthadsevereOUD(addiction).

Tomitigateaddictionrisk,physiciansshouldadheretotheCDCGuidelineforPrescribingOpioidsforChronicPain.Beforeprescribing,physiciansshouldassesspainandfunctioning,considerifnon-opioidtreatmentoptionsareappropriate,discussatreatmentplanwiththepatient,evaluatethepatient’sriskofharmormisuse,andco-prescribenaloxonetomitigatetheriskfor

38

29

39

13

overdose(seeNIDA'swebpageonnaloxone).Whenfirstprescribingopioids,physiciansshouldgivethelowesteffectivedosefortheshortesttherapeuticduration.Astreatmentcontinues,thepatientshouldbemonitoredatregularintervals,andopioidtreatmentshouldbecontinuedonlyifmeaningfulclinicalimprovementsinpainandfunctioningareseenwithoutharm.

CNSDepressants

WhatareCNSdepressants?

CNSdepressants,acategorythatincludestranquilizers,sedatives,andhypnotics,aresubstancesthatcanslowbrainactivity.Thispropertymakesthemusefulfortreatinganxietyandsleepdisorders.Thefollowingareamongthemedicationscommonlyprescribedforthesepurposes :

Benzodiazepines,suchasdiazepam(Valium ),clonazepam(Klonopin ),andalprazolam(Xanax ),aresometimesprescribedtotreatanxiety,acutestressreactions,andpanicattacks.Clonazepammayalsobeprescribedtotreatseizuredisordersandinsomnia.Themoresedatingbenzodiazepines,suchastriazolam(Halcion )andestazolam(Prosom )areprescribedforshort-termtreatmentofsleepdisorders.Usually,benzodiazepinesarenotprescribedforlong-termusebecauseofthehighriskfordevelopingtolerance,dependence,oraddiction.

Non-benzodiazepinesleepmedications,suchaszolpidem(Ambien ),eszopiclone(Lunesta ),andzaleplon(Sonata ),knownasz-drugs,haveadifferentchemicalstructurebutactonthesameGABAtypeAreceptorsinthebrainasbenzodiazepines.Theyarethoughttohavefewersideeffectsandlessriskofdependencethanbenzodiazepines.

Barbiturates,suchasmephobarbital(Mebaral ),

29

40

®

® ®

® ®

® ® ®

®

®

14

phenobarbital(Luminal ),andpentobarbitalsodium(Nembutal ),areusedlessfrequentlytoreduceanxietyortohelpwithsleepproblemsbecauseoftheirhigherriskofoverdosecomparedtobenzodiazepines.However,theyarestillusedinsurgicalproceduresandtotreatseizuredisorders.

HowdoCNSdepressantsaffectthebrainandbody?

MostCNSdepressantsactonthebrainbyincreasingactivityatreceptorsfortheinhibitoryneurotransmittergamma-aminobutyricacid(GABA).AlthoughthedifferentclassesofCNSdepressantsworkinuniqueways,itisthroughtheirabilitytoincreaseGABAsignaling—therebyincreasinginhibitionofbrainactivity—thattheyproduceadrowsyorcalmingeffectthatismedicallybeneficialtothosesufferingfromanxietyorsleepdisorders.

WhatarethepossibleconsequencesofCNSdepressantmisuse?

Despitetheirbeneficialtherapeuticeffects,benzodiazepinesandbarbiturateshavethepotentialformisuseandshouldbeusedonlyasprescribed. Theuseofnon-benzodiazepinesleepaids,orz-drugs,islesswell-studied,butcertainindicatorshaveraisedconcernabouttheirmisusepotentialaswell.

Duringthefirstfewdaysoftakingadepressant,apersonusuallyfeelssleepyanduncoordinated,butasthebodybecomesaccustomedtotheeffectsofthedrugandtolerancedevelops,thesesideeffectsbegintodisappear.Ifoneusesthesedrugslongterm,heorshemayneedlargerdosestoachievethetherapeuticeffects.Continuedusecanalsoleadtodependenceandwithdrawalwhenuseisabruptlyreducedorstopped(see"UnderstandingDependence,Addiction,andTolerance").BecauseCNSdepressantsworkbyslowingthebrain’sactivity,whenanindividualstopstakingthem,therecanbeareboundeffect,

®

®

40

40

41

40

15

resultinginseizuresorotherharmfulconsequences.

Althoughwithdrawalfrombenzodiazepinescanbeproblematic,itisrarelylifethreatening,whereaswithdrawalfromprolongeduseofbarbituratescanhavelife-threateningcomplications.Therefore,someonewhoisthinkingaboutdiscontinuingaCNSdepressantorwhoissufferingwithdrawalafterdiscontinuinguseshouldspeakwithaphysicianorseekimmediatemedicaltreatment.

Stimulants

Whatarestimulants?

Stimulantsincreasealertness,attention,andenergy,aswellaselevatebloodpressure,heartrate,andrespiration.Historically,stimulantswereusedtotreatasthmaandotherrespiratoryproblems,obesity,neurologicaldisorders,andavarietyofotherailments.Butastheirpotentialformisuseandaddictionbecameapparent,thenumberofconditionstreatedwithstimulantshasdecreased. Now,stimulantsareprescribedforthetreatmentofonlyafewhealthconditions,includingattention-deficithyperactivitydisorder(ADHD),narcolepsy,andoccasionallytreatment-resistantdepression.

Howdostimulantsaffectthebrainandbody?

Stimulants,suchasdextroamphetamine(Dexedrine ,Adderall )andmethylphenidate(Ritalin ,Concerta ),actinthebrainonthefamilyofmonoamineneurotransmittersystems,whichincludenorepinephrineanddopamine.Stimulantsenhancetheeffectsofthesechemicals.Anincreaseindopaminesignalingfromnonmedicaluseofstimulantscaninduceafeelingofeuphoria,and

40

42

43

44–46

® ®

® ®

16

thesemedications’effectsonnorepinephrineincreasebloodpressureandheartrate,constrictbloodvessels,increasebloodglucose,andopenupbreathingpassages.

Whatarethepossibleconsequencesofstimulantmisuse?

Aswithotherdrugsinthestimulantcategory,suchascocaine,itispossibleforpeopletobecomedependentonoraddictedtoprescriptionstimulants.Withdrawalsymptomsassociatedwithdiscontinuingstimulantuseincludefatigue,depression,anddisturbedsleeppatterns.Repeatedmisuseofsomestimulants(sometimeswithinashortperiod)canleadtofeelingsofhostilityorparanoia,orevenpsychosis. Further,takinghighdosesofastimulantmayresultindangerouslyhighbodytemperatureandanirregularheartbeat.Thereisalsothepotentialforcardiovascularfailureorseizures.

CognitiveEnhancers

Thedramaticincreasesinstimulantprescriptionsoverthelast2decadeshaveledtotheirgreateravailabilityandtoincreasedriskfordiversionandnonmedicaluse. Whentakentoimproveproperlydiagnosedconditions,thesemedicationscangreatlyenhanceapatient’squalityoflife.However,becausemanyperceivethemtobegenerallysafeandeffective,prescriptionstimulantssuchasAdderall andModafinil arebeingmisusedmorefrequently.

Stimulantsincreasewakefulness,motivation,andaspectsofcognition,learning,andmemory.Somepeopletakethesedrugsintheabsenceofmedicalneedinanefforttoenhancementalperformance. Militarieshavelongusedstimulantstoincreaseperformanceinthefaceoffatigue,andtheUnitedStatesArmedForcesallowfortheiruseinlimitedoperationalsettings. Thepracticeisnowreportedbysomeprofessionalstoincreasetheir

47

31

47

48

® ®

49

50

17

productivity,byolderpeopletooffsetdecliningcognition,andbybothhighschoolandcollegestudentstoimprovetheiracademicperformance.

Nonmedicaluseofstimulantsforcognitiveenhancementposespotentialhealthrisks,includingaddiction,cardiovascularevents,andpsychosis.Theuseofpharmaceuticalsforcognitiveenhancementhasalsosparkeddebateovertheethicalimplicationsofthepractice.Issuesoffairnessariseifthosewithaccessandwillingnesstotakethesedrugshaveaperformanceedgeoverothers,andimplicitcoerciontakesplaceifacultureofcognitiveenhancementgivestheimpressionthatapersonmusttakedrugsinordertobecompetitive.

49,51

18

Areprescriptiondrugssafetotakewhenpregnant?

Someprescriptionmedicationstakenbyapregnantwomancancauseherbabytodevelopdependence,whichcanresultinwithdrawalsymptomsafterbirth,knownasneonatalabstinencesyndrome(NAS).Thiscanrequireaprolongedstayinneonatalintensivecareand,inthecaseofopioids,treatmentwithmedication(see"SexandGenderDifferencesinSubstanceUseDisorderTreatment"inNIDA'sSubstanceUseinWomenResearchReport).Womenshouldconsultwiththeirdoctorstodeterminewhichmedicationstheycancontinuetakingduringpregnancy.

Opioidpainmedicationsrequireparticularattention;risingratesofNAShavebeenassociatedwithincreasesintheprescriptionofopioidsforpaininpregnantwomen.NASassociatedwithopioiduse(heroinor

Photoby©Thinkstock.com/GeorgeDoyle

19

prescriptionopioids)increasedfivefoldfrom2000to2012,withahigherrateofincreaseinmorerecentyears.52,53

20

Howcanprescriptiondrugmisusebeprevented?

Clinicians,Patients,andPharmacists

Physicians,theirpatients,andpharmacistsallcanplayaroleinidentifyingandpreventingnonmedicaluseofprescriptiondrugs.

Clinicians.Morethan84percentofAmericanshadcontactwithahealthcareprofessionalin2016 ,placingdoctorsinauniquepositiontoidentifynonmedicaluseofprescriptiondrugsandtakemeasurestopreventtheescalationofapatient’smisusetoasubstanceusedisorder.Byaskingaboutalldrugs,physicianscanhelptheirpatientsrecognizewhetheraproblemexists,provideorreferthemtoappropriatetreatment,andsetrecoverygoals.Evidence-basedscreeningtoolsfornonmedicaluseofprescriptiondrugscanbeincorporatedintoroutinemedicalvisits(seetheNIDAMEDwebpageforresourcesformedicalandhealthprofessionals).Doctorsshouldalsotakenoteofrapidincreasesintheamountofmedicationneededorfrequent,unscheduledrefillrequests.Doctorsshouldbealerttothefactthatthosemisusingprescriptiondrugsmayengagein"doctorshopping"—movingfromprovidertoprovider—inanefforttoobtainmultipleprescriptionsfortheirdrug(s)ofchoice.

Prescriptiondrugmonitoringprograms(PDMPs),state-runelectronicdatabasesusedtotracktheprescribinganddispensingofcontrolledprescriptiondrugstopatients,arealsoimportanttoolsforpreventingandidentifyingprescriptiondrugmisuse.Whileresearchregardingtheimpactoftheseprogramsiscurrentlymixed,theuseofPDMPsinsomestateshasbeenassociatedwithlowerratesofopioidprescribingandoverdose ,thoughissuesofbestpractices,easeofuse,andinteroperabilityremaintoberesolved.

In2015,thefederalgovernmentlaunchedaninitiativedirectedtowardreducingopioidmisuseandoverdose,inpartbypromotingmore

54

55–58

21

cautiousandresponsibleprescribingofopioidmedications.Inlinewiththeseefforts,in2016theCentersforDiseaseControlandPrevention(CDC)publisheditsCDCGuidelineforPrescribingOpioidsforChronicPaintoestablishclinicalstandardsforbalancingthebenefitsandrisksofchronicopioidtreatment. Then,in2017,PresidentTrumpestablishedthePresident'sCommissiononCombatingDrugAddictionandtheOpioidCrisis.Thecommissionoutlinedseveralpriorityareasaimedatimprovingthepreventionandtreatmentofopioidaddiction.

Coordinatedfederaleffortstoreduceopioidaddictionandoverdoseareongoing.

Preventingorstoppingnonmedicaluseofprescriptiondrugsisanimportantpartofpatientcare.However,certainpatientscanbenefitfromprescriptionstimulants,sedatives,oropioidpainrelievers.Therefore,physiciansshouldbalancethelegitimatemedicalneedsofpatientswiththepotentialriskformisuseandrelatedharms.

Patients.Patientscantakestepstoensurethattheyuseprescriptionmedicationsappropriatelyby:

followingthedirectionsasexplainedonthelabelorbythepharmacist

beingawareofpotentialinteractionswithotherdrugsaswellasalcohol

neverstoppingorchangingadosingregimenwithoutfirstdiscussingitwiththedoctor

neverusinganotherperson’sprescriptionandnevergivingtheirprescriptionmedicationstoothers

storingprescriptionstimulants,sedatives,andopioidssafely

Additionally,patientsshouldproperlydiscardunusedorexpiredmedicationsbyfollowingU.S.FoodandDrugAdministration(FDA)guidelinesorvisitingU.S.DrugEnforcementAdministrationcollection

29

55

22

sites. Inadditiontodescribingtheirmedicalproblem,patientsshouldalwaysinformtheirhealthcareprofessionalsaboutalltheprescriptions,over-the-countermedicines,anddietaryandherbalsupplementstheyaretakingbeforetheyobtainanyothermedications.

Pharmacists.Pharmacistscanhelppatientsunderstandinstructionsfortakingtheirmedicationsalongwithhowthemedicationworksfortheircondition.Inaddition,bybeingwatchfulforprescriptionfalsificationsoralterations,pharmacistscanserveasthefirstlineofdefenseinrecognizingproblematicpatternsinprescriptiondruguse.Somepharmacieshavedevelopedhotlinestoalertotherpharmaciesintheregionwhentheydetectafraudulentprescription.Alongwithphysicians,pharmacistscanusePDMPstohelptrackopioid-prescribinganddispensingpatternsinpatients.

MedicationFormulationandRegulation

55

©iStock.com/HconQ

23

Manufacturersofprescriptiondrugscontinuetoworkonnewformulationsofopioidmedications,knownasabuse-deterrentformulations(ADF),whichincludetechnologiesdesignedtopreventpeoplefrommisusingthembysnortingorinjection.Approachescurrentlybeingusedorstudiedforuseinclude:

physicalorchemicalbarriersthatpreventthecrushing,grinding,ordissolvingofdrugproducts

agonist/antagonistcombinationsthatcauseanantagonist(whichwillcounteractthedrugeffect)tobereleasediftheproductismanipulated

aversivesubstancesthatareaddedtocreateunpleasantsensationsifthedrugistakeninawayotherthandirected

deliverysystemssuchaslong-actinginjectionsorimplantsthatslowlyreleasethedrugovertime

newmolecularentitiesorprodrugsthatattachachemicalextensiontoadrugthatrendersitinactiveunlessitistakenorally

SeveralADFopioidsareonthemarket,andtheFDAhasalsocalledforthedevelopmentofADFstimulants. Abuse-deterrentformulationshavebeenshowntodecreasetheillicitvalueofdrugs. Medicationregulationhasbeenshowntobeeffectiveindecreasingtheprescribingofopioidmedications.In2014,theDrugEnforcementAdministrationmovedhydrocodoneproductsfromscheduleIIItothemorerestrictivescheduleII,whichresultedinadecreaseinhydrocodoneprescribingthatdidnotresultinanyattendantincreasesintheprescribingofotheropioids.

DevelopmentofSaferMedications

Thedevelopmentofeffective,non-addictingpainmedicationsisapublichealthpriority.Agrowingnumberofolderadultsandanincreasingnumberofinjuredmilitaryservicemembersaddtotheurgencyoffindingnewtreatments.Researchersare

56

56

32

24

exploringalternativetreatmentapproachesthattargetothersignalingsystemsinthebodysuchastheendocannabinoidsystem,whichisalsoinvolvedinpain. Moreresearchisalsoneededtobetterunderstandeffectivechronicpainmanagement,includingidentifyingfactorsthatpredisposesomepatientstosubstanceusedisordersanddevelopingmeasurestopreventthenonmedicaluseofprescriptionmedications.

57

25

Howcanprescriptiondrugaddictionbetreated?

Yearsofresearchhaveshownthatsubstanceusedisordersarebraindisordersthatcanbetreatedeffectively.Treatmentmusttakeintoaccountthetypeofdrugusedandtheneedsoftheindividual.Successfultreatmentmayneedtoincorporateseveralcomponents,includingdetoxification,counseling,andmedications,whenavailable.Multiplecoursesoftreatmentmaybeneededforthepatienttomakeafullrecovery.

Thetwomaincategoriesofdrugusedisordertreatmentarebehavioraltreatments(suchascontingencymanagementandcognitive-behavioraltherapy)andmedications.Behavioraltreatmentshelppatientsstopdrugusebychangingunhealthypatternsofthinkingandbehavior;teachingstrategiestomanagecravingsandavoidcuesandsituationsthatcouldleadtorelapse;or,insomecases,providingincentivesforabstinence.Behavioraltreatments,whichmaytaketheformofindividual,family,orgroupcounseling,alsocanhelppatientsimprovetheirpersonalrelationshipsandtheirabilitytofunctionatworkandinthecommunity.

Addictiontoprescriptionopioidscanadditionallybetreatedwithmedicationsincludingbuprenorphine,methadone,andnaltrexone(see"MedicationsforOpioidUseDisorder"below).Thesedrugscanpreventotheropioidsfromaffectingthebrain(naltrexone)orrelievewithdrawalsymptomsandcravings(buprenorphineandmethadone),helpingthepatientavoidrelapse.Medicationsforthetreatmentofopioidaddictionareoftenadministeredincombinationwithpsychosocialsupportsorbehavioraltreatments,knownasmedication-assistedtreatment(MAT). Amedicationtoreducethephysicalsymptomsofwithdrawal(lofexidine)isalsoavailable.

MedicationsforOpioidUseDisorder

58

58

59

26

Methadoneisasyntheticopioidagonistthatpreventswithdrawalsymptomsandrelievesdrugcravings.Itworksbyactingonthesamemu-opioidreceptorsasotheropioidssuchasheroin,morphine,andopioidpainmedicationsbutatlessintensityandforlongerduration.Methadonehasbeenusedsuccessfullyformorethan40yearstotreatheroinaddictionbutisgenerallyonlyavailablethroughspeciallylicensedopioidtreatmentprograms.

Buprenorphineisapartialopioidagonist—itbindstothemu-opioidreceptorbutonlypartiallyactivatesit—andcanbeprescribedbycertifiedphysicians,nursepractitioners,andphysicianassistantsinanofficesetting.Likemethadone,itcanreducecravingsandiswelltoleratedbypatients.In2016,theU.S.FoodandDrugAdministration(FDA)approvedtheNIDA-supporteddevelopmentofanimplantableformulationofbuprenorphinethatprovides6monthsofsustainedmedicationdelivery;andin2017,amonth-longinjectableformulationwasapproved.Theseformulationseliminatetheneedfordailydosingandwillgivepatientsgreatereaseintreatmentadherence,especiallyiftheylivefarfromtheirtreatmentprovider.

Therehasbeenapopularmisconceptionthatmethadoneandbuprenorphinereplaceoneaddictionwithanother.Thisisnotthecase.Inpeopleaddictedtoopioids,thesedrugsdonotproduceahighbutsimplypreventwithdrawalandcravingsothattheycanfunctioninlifeandengagewithtreatmentwhilebalanceisrestoredtobraincircuitsthathavebeenaffectedbytheirdisorder.

Naltrexoneisanothertypeofmedication,anantagonist,whichpreventsotheropioidsfrombindingtoandactivatingopioidreceptors.Aninjectable,long-actingformofnaltrexone(Vivitrol )canbeausefultreatmentchoiceforpatientswhodonothavereadyaccesstohealthcareorwhostrugglewithtakingtheirmedicationsregularly.

Whilemedicationsarethestandardofcarefortreatingopioiduse

®

27

disorder,farfewerpeoplereceivemedicationsthancouldpotentiallybenefitfromit.Notallpeoplewithopioidusedisorderseektreatment.Evenwhentheyseektreatment,theywillnotnecessarilyreceivemedications.Themostrecenttreatmentadmissionsdataavailableshowthatonly21percentofpeopleadmittedforprescriptionopioidusedisorderhaveatreatmentplanthatincludesmedications. However,evenifthenationwideinfrastructurewereoperatingatcapacity,between1.3and1.4millionmorepeoplehaveopioidusedisorderthancouldcurrentlybetreatedwithmedications;thisisduetolimitedavailabilityofopioidtreatmentprogramsthatcandispensemethadoneandtheregulatorylimitonthenumberofpatientsthatphysicianscantreatwithbuprenorphine. Coordinatedeffortsareunderwaynationwidetoexpandaccesstoopioidusedisordermedications,includingarecentincreaseinthebuprenorphinepatientlimitfrom100patientsto275forqualifiedphysicianswhorequestthehigherlimit.

NIDAissupportingresearchneededtodeterminethemosteffectivewaystoimplementmedicationsforopioidusedisorder.Forexample,recentworkhasshownthatbuprenorphinemaintenancetreatmentismoreeffectivethantaperingpatientsoffofbuprenorphine. Also,startingbuprenorphinetreatmentwhenapatientisadmittedtotheemergencydepartment,suchasforanoverdose,isamoreeffectivewaytoengageapatientintreatmentthanreferralorbriefintervention. Finally,datahaveshownthattreatmentwithmethadone,buprenorphine,ornaltrexoneforincarceratedindividualsimprovespost-releaseoutcomes.

Formoreinformationonmedicationstotreatopioidusedisorder,seeNIDA’sMedicationstoTreatOpioidUseDisorderResearchReport.

60

61

62

63

64

65–67

28

ReversinganOpioidOverdosewithNaloxone

Theopioidoverdose-reversaldrugnaloxoneisanopioidantagonistthatcanrapidlyrestorenormalrespirationtoapersonwhohasstoppedbreathingasaresultofoverdoseonprescriptionopioidsorheroin.Naloxonecanbeusedbyemergencymedicalpersonnel,firstresponders,andbystanders.Formoreinformation,visitNIDA'swebpageonnaloxone.

TreatingAddictiontoCNSDepressants

PatientsaddictedtoCNSdepressantssuchastranquilizers,sedatives,andhypnoticsshouldnotattempttostoptakingthemontheirown.Withdrawalsymptomsfromthesedrugscanbesevereand,inthecaseofcertainmedications,potentiallylife-threatening. ResearchontreatingaddictiontoCNSdepressantsissparse;however,patientswhoaredependentonthesemedicationsshouldundergomedicallysuperviseddetoxificationbecausethedosagetheytakeshouldbetaperedgradually.Inpatientoroutpatientcounselingcanhelpindividualsthroughthisprocess.Cognitive-behavioraltherapy,whichfocusesonmodifyingthepatient’sthinking,expectations,andbehaviorswhileincreasingskillsforcopingwithvariouslifestressors,hasalsobeenusedsuccessfullytohelpindividualsadapttodiscontinuingbenzodiazepines.

OftenCNSdepressantmisuseoccursinconjunctionwiththeuseofotherdrugs(polydruguse),suchasalcoholoropioids. Insuchcases,thetreatmentapproachshouldaddressthemultipleaddictions.

Atthistime,therearenoFDA-approvedmedicationsfortreatingaddictiontoCNSdepressants,thoughresearchisongoinginthisarea.

31

68

69

29

TreatingAddictiontoPrescriptionStimulants

TreatmentofaddictiontoprescriptionstimulantssuchasAdderallandConcerta isbasedonbehavioraltherapiesthatareeffectivefortreatingcocaineandmethamphetamineaddiction.Atthistime,therearenoFDA-approvedmedicationsfortreatingstimulantaddiction.NIDAissupportingresearchinthisarea.

Dependingonthepatient,thefirststepsintreatingprescriptionstimulantaddictionmaybetotaperthedrugdosageandattempttoeasewithdrawalsymptoms.Behavioraltreatmentmaythenfollowthedetoxificationprocess(see"BehavioralTherapies"inNIDA'sPrinciplesofDrugAddictionTreatment:AResearch-BasedGuide).

®

®

41

30

WherecanIgetfurtherinformationaboutprescriptiondrugmisuse?

Tolearnmoreaboutprescriptiondrugsandotherdrugs,visittheNIDAwebsiteatdrugabuse.govorcontacttheDrugPubsResearchDisseminationCenterat877-NIDA-NIH(877-643-2644;TTY/TDD:240-645-0228).

TheNIDA'swebsiteincludes:

informationondrugsandrelatedhealthconsequences

NIDApublications,news,andevents

resourcesforhealthcareprofessionals

fundinginformation(includingprogramannouncementsanddeadlines)

internationalactivities

linkstorelatedwebsites(accesstowebsitesofmanyotherorganizationsinthefield)

informationinSpanish(enespañol)

NIDAwebsitesandwebpages

drugabuse.gov

teens.drugabuse.gov

easyread.drugabuse.gov

drugabuse.gov/drugs-abuse/prescription-drugs-cold-medicines

researchstudies.drugabuse.gov

31

irp.drugabuse.gov

Forphysicianinformation

NIDAMED:drugabuse.gov/nidamed

Otherwebsites

Informationaboutprescriptiondrugmisuseisalsoavailablethroughthefollowingwebsites:

SubstanceAbuseandMentalHealthServicesAdministration:samhsa.gov

U.S.DrugEnforcementAdministration:dea.gov

MonitoringtheFuture:monitoringthefuture.org

PartnershipforDrug-FreeKids:drugfree.org/drug-guide

ThispublicationisavailableforyouruseandmaybereproducedinitsentiretywithoutpermissionfromNIDA.Citationofthesourceisappreciated,usingthefollowinglanguage:Source:NationalInstituteonDrugAbuse;NationalInstitutesofHealth;U.S.DepartmentofHealthandHumanServices.

32

References

1. BlancoC,AldersonD,OgburnE,etal.Changesintheprevalenceofnon-medicalprescriptiondruguseanddrugusedisordersintheUnitedStates:1991-1992and2001-2002.DrugAlcoholDepend.2007;90(2-3):252-260.doi:10.1016/j.drugalcdep.2007.04.005

2. CenterforBehavioralHealthStatisticsandQuality.TreatmentEpisodeDataSet(TEDS):2003-2013.NationalAdmissionstoSubstanceAbuseTreatmentServices.Rockville,MD:SubstanceAbuseandMentalHealthServicesAdministration;2015.http://www.samhsa.gov/data/sites/default/files/2013_Treatment_Episode_Data_Set_National/2013_Treatment_Episode_Data_Set_National.pdf

3. CenterforBehavioralHealthStatisticsandQuality.DrugAbuseWarningNetwork:2011:SelectedTablesofNationalEstimatesofDrug-RelatedEmergencyDepartmentVisits.Rockville,MD:SubstanceAbuseandMentalHealthServicesAdministration

4. JonesCM,McAninchJK.EmergencyDepartmentVisitsandOverdoseDeathsFromCombinedUseofOpioidsandBenzodiazepines.AmJPrevMed.2015;49(4):493-501.doi:10.1016/j.amepre.2015.03.040

5. RuddRA,AleshireN,ZibbellJE,GladdenRM.IncreasesinDrugandOpioidOverdoseDeaths—UnitedStates,2000–2014.CentersforDiseaseControlandPrevention;2016.https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6450a3.htm?s_cid=mm6450a3_w.AccessedNovember7,2017.

6. CentersforDiseaseControlandPrevention.PrescriptionOpioidData.https://www.cdc.gov/drugoverdose/data/prescribing.html.PublishedAugust31,2018.AccessedSeptember18,2018.

7. CenterforBehavioralHealthStatisticsandQuality.Resultsfromthe2017NationalSurveyonDrugUseandHealth:DetailedTables.Rockville(MD):SAMHSA;2018.https://www.samhsa.gov/data/report/2017-nsduh-detailed-tables.AccessedOctober19,2018.

8. CentersforDiseaseControlandPrevention.VitalSigns:Overdoses

33

ofPrescriptionOpioidPainRelievers---UnitedStates,1999--2008.https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6043a4.htm.AccessedSeptember18,2018.

9. ManchikantiL,FellowsB,AilinaniH,PampatiV.Therapeuticuse,abuse,andnonmedicaluseofopioids:aten-yearperspective.PainPhysician.2010;13(5):401-435.

10. DaniulaityteR,FalckR,CarlsonRG."I'mnotafraidofthoseonesjust‘causethey’vebeenprescribed":Perceptionsofriskamongillicitusersofpharmaceuticalopioids.IntJDrugPolicy.2012;23(5):374-384.doi:10.1016/j.drugpo.2012.01.012

11. WebsterPC.Oxycodoneclassactionlawsuitfiled.CMAJCanMedAssocJ.2012;184(7):E345-E346.doi:10.1503/cmaj.109-4158

12. QatoDM,AlexanderGC,ContiRM,JohnsonM,SchummP,LindauST.UseofPrescriptionandOver-the-counterMedicationsandDietarySupplementsAmongOlderAdultsintheUnitedStates.JAMA.2008;300(24):2867.doi:10.1001/jama.2008.892

13. MiechR,JohnstonL,O’MalleyPM,KeyesKM,HeardK.PrescriptionOpioidsinAdolescenceandFutureOpioidMisuse.Pediatrics.2015;136(5):e1169-e1177.doi:10.1542/peds.2015-1364

14. MackKA,JonesCM,PaulozziLJ.VitalSigns:OverdosesofPrescriptionOpioidPainRelieversandOtherDrugsAmongWomen—UnitedStates,1999–2010.;2013:537-542.https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6226a3.htm.AccessedJanuary31,2018.

15. CenterforBehavioralHealthStatisticsandQuality.Resultsfromthe2017NationalSurveyonDrugUseandHealth:DetailedTables.Rockville,MD:SubstanceAbuseandMentalHealthServicesAdministration;2018.

16. MiechR,SchulenbergJ,JohnstonL,BachmanJ,O’MalleyP,PatrickM.MonitoringtheFutureNationalAdolescentDrugTrendsin2017:FindingsReleased.AnnArbor,MI:InstituteforSocialResearch,TheUniversityofMichigan;2017.http://www.monitoringthefuture.org//pressreleases/17drugpr.pdf.AccessedJanuary2,2018.

34

17. McCabeSE,WestBT,TeterCJ,BoydCJ.MedicalandnonmedicaluseofprescriptionopioidsamonghighschoolseniorsintheUnitedStates.ArchPediatrAdolescMed.2012;166(9):797-802.doi:10.1001/archpediatrics.2012.85

18. BoydCJ,EstebanS,TeterCJ.MedicalandnonmedicaluseofprescriptionpainmedicationbyyouthinaDetroit-areapublicschooldistrict.DrugAlcoholDepend.2006;81(1):37-45.doi:10.1016/j.drugalcdep.2005.05.017

19. McCabeSE,TeterCJ,BoydCJ.Illicituseofprescriptionpainmedicationamongcollegestudents.DrugAlcoholDepend.2005;77(1):37-47.doi:10.1016/j.drugalcdep.2004.07.005

20. YoungAM,GloverN,HavensJR.NonmedicaluseofprescriptionmedicationsamongadolescentsintheUnitedStates:asystematicreview.JAdolescHealthOffPublSocAdolescMed.2012;51(1):6-17.doi:10.1016/j.jadohealth.2012.01.011

21. WangR,ChenL,FanL,etal.IncidenceandEffectsofPolypharmacyonClinicalOutcomeamongPatientsAged80+:AFive-YearFollow-UpStudy.PloSOne.2015;10(11):e0142123.doi:10.1371/journal.pone.0142123

22. CottoJH,DavisE,DowlingGJ,ElcanoJC,StatonAB,WeissSRB.Gendereffectsondruguse,abuse,anddependence:aspecialanalysisofresultsfromtheNationalSurveyonDrugUseandHealth.GendMed.2010;7(5):402-413.doi:10.1016/j.genm.2010.09.004

23. CDCVitalSigns:PrescriptionPainkillerOverdoses:Agrowingepidemic,especiallyamongwomen.CentersforDiseaseControlandPrevention.http://www.cdc.gov/vitalsigns/prescriptionpainkilleroverdoses/index.html.PublishedMarch23,2017.AccessedMarch27,2017.

24. RonanMV,HerzigSJ.HospitalizationsRelatedToOpioidAbuse/DependenceAndAssociatedSeriousInfectionsIncreasedSharply,2002-12.HealthAffProjHope.2016;35(5):832-837.doi:10.1377/hlthaff.2015.1424

35

25. JonesCM,PaulozziLJ,MackKA.AlcoholInvolvementinOpioidPainRelieverandBenzodiazepineDrugAbuse–RelatedEmergencyDepartmentVisitsandDrug-RelatedDeaths—UnitedStates,2010.https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6340a1.htm.AccessedSeptember18,2018.

26. PentelP.ToxicityofOver-the-CounterStimulants.JAMA.1984;252(14):1898-1903.

27. GutsteinH,AkilH.OpioidAnalgesics.In:Goodman&Gilman’sthePharmacologicalBasisofTherapeutics.11thed.McGraw-Hill;2006:547-590.

28. DowellD,HaegerichTM,ChouR.CDCGuidelineforPrescribingOpioidsforChronicPain—UnitedStates,2016.;2016.https://www.cdc.gov/mmwr/volumes/65/rr/rr6501e1.htm.AccessedSeptember18,2018.

29. LeeM,SilvermanSM,HansenH,PatelVB,ManchikantiL.Acomprehensivereviewofopioid-inducedhyperalgesia.PainPhysician.2011;14(2):145-161.

30. HartC,KsirC.Drugs,Society,andHumanBehavior.15edition.NewYork,NY:McGraw-HillEducation;2012.

31. JonesCM,LuriePG,ThrockmortonDC.EffectofUSDrugEnforcementAdministration’sReschedulingofHydrocodoneCombinationAnalgesicProductsonOpioidAnalgesicPrescribing.JAMAInternMed.2016;176(3):399-402.doi:10.1001/jamainternmed.2015.7799

32. Oxycodone:MedlinePlusDrugInformation.https://medlineplus.gov/druginfo/meds/a682132.html.AccessedSeptember18,2018.

33. Oxymorphone:MedlinePlusDrugInformation.https://medlineplus.gov/druginfo/meds/a610022.html.AccessedSeptember18,2018.

34. CiceroTJ,EllisMS.Abuse-DeterrentFormulationsandthePrescriptionOpioidAbuseEpidemicintheUnitedStates:LessonsLearnedFromOxyContin.JAMAPsychiatry.2015;72(5):424-430.

36

doi:10.1001/jamapsychiatry.2014.3043

35. O’BrienCP,DackisC.PrinciplesofthePharmacotherapyofAddictiveDisorders.In:NeurobiologyofMentalIllness.Third.OxfordUniversityPress;2006.

36. O’BrienCP.DrugAddictionandDrugAbuse.In:Goodman&Gilman’sthePharmacologicalBasisofTherapeutics.11thed.McGraw-Hill;2006:607-627.

37. InstituteofMedicine(US)CommitteeonAdvancingPainResearch,Care,andEducation.RelievingPaininAmerica:ABlueprintforTransformingPrevention,Care,Education,andResearch.Washington(DC):NationalAcademiesPress(US);2011.http://www.ncbi.nlm.nih.gov/books/NBK91497/.

38. ChouR,TurnerJA,DevineEB,etal.Theeffectivenessandrisksoflong-termopioidtherapyforchronicpain:asystematicreviewforaNationalInstitutesofHealthPathwaystoPreventionWorkshop.AnnInternMed.2015;162(4):276-286.doi:10.7326/M14-2559

39. HypnoticsandSedatives.In:Goodman&Gilman’sthePharmacologicalBasisofTherapeutics.11thed.McGraw-Hill;2006.

40. GunjaN.TheclinicalandforensictoxicologyofZ-drugs.JMedToxicolOffJAmCollMedToxicol.2013;9(2):155-162.doi:10.1007/s13181-013-0292-0

41. SellersEM.Alcohol,barbiturateandbenzodiazepinewithdrawalsyndromes:clinicalmanagement.CMAJCanMedAssocJ.1988;139(2):113-120.

42. CiccaroneD.StimulantAbuse:Pharmacology,Cocaine,Methamphetamine,Treatment,AttemptsatPharmacotherapy.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3056348/.AccessedSeptember18,2018.

43. ScammellTE.Narcolepsy.NEnglJMed.2015;373(27):2654-2662.doi:10.1056/NEJMra1500587

44. SantoshPJ,SattarS,CanagaratnamM.Efficacyandtolerabilityof

37

pharmacotherapiesforattention-deficithyperactivitydisorderinadults.CNSDrugs.2011;25(9):737-763.doi:10.2165/11593070-000000000-00000

45. CorpSA,GitlinMJ,AltshulerLL.Areviewoftheuseofstimulantsandstimulantalternativesintreatingbipolardepressionandmajordepressivedisorder.JClinPsychiatry.2014;75(9):1010-1018.doi:10.4088/JCP.13r08851

46. WestfallT,WestfallD.AdrenergicAgonistsandAntagonists.In:Goodman&Gilman’sthePharmacologicalBasisofTherapeutics.Vol11.McGraw-Hill;2006:237-295.

47. McCabeSE,WestBT.MedicalandNonmedicalUseofPrescriptionStimulants:ResultsFromaNationalMulticohortStudy.JAmAcadChildAdolescPsychiatry.2013;52(12):1272-1280.doi:10.1016/j.jaac.2013.09.005

48. SchelleKJ,FaulmullerN,CaviolaL,HewstoneM.Attitudestowardpharmacologicalcognitiveenhancement—areview.FrontSystNeurosci.2014;8.doi:10.3389/fnsys.2014.00053

49. CaldwellJA,CaldwellJL.Fatigueinmilitaryaviation:anoverviewofUSmilitary-approvedpharmacologicalcountermeasures.AviatSpaceEnvironMed.2005;76(7Suppl):C39-C51.

50. HymanSE.CognitiveEnhancement:PromisesandPerils.Neuron.2011;69(4):595-598.doi:10.1016/j.neuron.2011.02.012

51. ToliaVN,PatrickSW,BennettMM,etal.IncreasingincidenceoftheneonatalabstinencesyndromeinU.S.neonatalICUs.NEnglJMed.2015;372(22):2118-2126.doi:10.1056/NEJMsa1500439

52. PatrickSW,DavisMM,LehmannCU,CooperWO.Increasingincidenceandgeographicdistributionofneonatalabstinencesyndrome:UnitedStates2009to2012.JPerinatolOffJCalifPerinatAssoc.2015;35(8):650-655.doi:10.1038/jp.2015.36

53. NationalCenterforHealthStatistics.AmublatoryCareUseandPhysicianOfficeVisits.

54. CenterforDrugEvaluationandResearch.SafeDisposalof

38

Medicines—DisposalofUnusedMedicines:WhatYouShouldKnow.https://www.fda.gov/Drugs/ResourcesForYou/Consumers/BuyingUsingMedicineSafely/EnsuringSafeUseofMedicine/SafeDisposalofMedicines/ucm186187.htmAccessedSeptember18,2018.

55. SimonK,WorthySL,BarnesMC,TarbellB.Abuse-deterrentformulations:transitioningthepharmaceuticalmarkettoimprovepublichealthandsafety.TherAdvDrugSaf.2015;6(2):67-79.doi:10.1177/2042098615569726

56. MaldonadoR,BañosJE,CabañeroD.Theendocannabinoidsystemandneuropathicpain.Pain.2016;157Suppl1:S23-S32.doi:10.1097/j.pain.0000000000000428

57. NationalInstituteonDrugAbuse.PrinciplesofDrugAddictionTreatment:AResearch-BasedGuide(ThirdEdition).Bethesda,MD:NationalInstitutesofHealth;2012.https://www.drugabuse.gov/publications/principles-drug-addiction-treatment-research-based-guide-third-edition/principles-effective-treatment.AccessedJanuary31,2018.

58. VolkowND,FriedenTR,HydePS,ChaSS.Medication-assistedtherapies—tacklingtheopioid-overdoseepidemic.NEnglJMed.2014;370(22):2063-2066.doi:10.1056/NEJMp1402780

59. CenterforBehavioralHealthStatisticsandQuality.TreatmentEpisodeDataSet(TEDS)2002-2012:NationalAdmissionstoSubstanceAbuseTreatmentServices.Rockville,MD:SubstanceAbuseandMentalHealthServicesAdministration;2014.http://www.samhsa.gov/data/sites/default/files/TEDS2012N_Web.pdf.

60. JonesCM,CampopianoM,BaldwinG,McCance-KatzE.Nationalandstatetreatmentneedandcapacityforopioidagonistmedication-assistedtreatment.AmJPublicHealth.2015;105(8):e55-e63.doi:10.2105/AJPH.2015.302664

61. ObamaAdministrationTakesMoreActionstoAddressthePrescriptionOpioidandHeroinEpidemic.https://obamawhitehouse.archives.gov/the-press-office/2016/07/05/obama-administration-takes-more-actions-address-prescription-opioid-and.

62. FiellinDA,SchottenfeldRS,CutterCJ,MooreBA,BarryDT,

39

O’ConnorPG.Primarycare-basedbuprenorphinetapervsmaintenancetherapyforprescriptionopioiddependence:arandomizedclinicaltrial.JAMAInternMed.2014;174(12):1947-1954.doi:10.1001/jamainternmed.2014.5302

63. D’OnofrioG,O’ConnorPG,PantalonMV,etal.Emergencydepartment-initiatedbuprenorphine/naloxonetreatmentforopioiddependence:arandomizedclinicaltrial.JAMA.2015;313(16):1636-1644.doi:10.1001/jama.2015.3474

64. GordonMS,KinlockTW,SchwartzRP,FitzgeraldTT,O’GradyKE,VocciFJ.Arandomizedcontrolledtrialofprison-initiatedbuprenorphine:prisonoutcomesandcommunitytreatmententry.DrugAlcoholDepend.2014;142:33-40.doi:10.1016/j.drugalcdep.2014.05.011

65. KinlockTW,GordonMS,SchwartzRP,O’GradyK,FitzgeraldTT,WilsonM.Arandomizedclinicaltrialofmethadonemaintenanceforprisoners:resultsat1-monthpost-release.DrugAlcoholDepend.2007;91(2-3):220-227.doi:10.1016/j.drugalcdep.2007.05.022

66. LeeJD,FriedmannPD,KinlockTW,etal.Extended-ReleaseNaltrexonetoPreventOpioidRelapseinCriminalJusticeOffenders.NEnglJMed.2016;374(13):1232-1242.doi:10.1056/NEJMoa1505409

67. DarkerC,SweeneyB,BarryJ,FarrellMF,Donnelly-SwiftE.Psychosocialinterventionstoreducesedativeuse,abuseanddependence.CochraneDatabaseSystRev./CD009652/ADDICTN_psychosocial-interventions-to-reduce-sedative-use-abuse-and-dependence.AccessedSeptember18,2018.

68. JonesJD,MogaliS,ComerSD.Polydrugabuse:areviewofopioidandbenzodiazepinecombinationuse.DrugAlcoholDepend.2012;125(1-2):8-18.doi:10.1016/j.drugalcdep.2012.07.004